SEPTRA Drug Patent Profile

Which patents cover Septra, and when can generic versions of Septra launch?

Septra is a drug marketed by Monarch Pharms and is included in three NDAs.

The generic ingredient in SEPTRA is sulfamethoxazole; trimethoprim. There are twenty-seven drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sulfamethoxazole; trimethoprim profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Septra

A generic version of SEPTRA was approved as sulfamethoxazole; trimethoprim by SUN PHARM INDUSTRIES on August 25^th, 1986.

Summary for SEPTRA

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	23
DailyMed Link:	SEPTRA at DailyMed

Recent Clinical Trials for SEPTRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 4
National Cancer Institute (NCI)	Phase 4
Cidara Therapeutics Inc.	Phase 3

See all SEPTRA clinical trials

US Patents and Regulatory Information for SEPTRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Monarch Pharms	SEPTRA	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018452-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	SEPTRA DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	SEPTRA	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	017598-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	SEPTRA	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for SEPTRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Monarch Pharms	SEPTRA	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-001	Approved Prior to Jan 1, 1982	4,209,513

International Patents for SEPTRA

See the table below for patents covering SEPTRA around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	7500930
United Kingdom	1499672
Luxembourg	71835
Czechoslovakia	220306	METHOD OF MANUFACTURING TABLETS HAVING SHORT BREAKDOWN PERIOD

Market Dynamics and Financial Trajectory for SEPTRA

Last updated: February 8, 2026

Overview

SEPTRA (sulfamethoxazole and trimethoprim) is an antibiotic combination primarily used to treat urinary tract infections, otitis media, and certain respiratory infections. Originally launched by Roche and later acquired by Pfizer, it has maintained a significant market position due to its clinical efficacy, affordability, and broad-spectrum activity.

Market Scope

As of 2022, the global antibiotic market is valued at approximately $51 billion, with sulfamethoxazole/trimethoprim (TMP/SMX) comprising a notable segment, estimated at $1.8 billion. SEPTRA accounts for a large share of this segment, especially in North America and Europe, driven by increasing bacterial resistance to other antibiotics and favoring established agents.

Market Drivers

• Antimicrobial Resistance (AMR): Rising resistance to newer antibiotics enhances demand for older, proven agents like SEPTRA.
• Prescription Practices: Continued preference in outpatient settings and for uncomplicated infections.
• Cost-effectiveness: Generic availability and low cost sustain its prescription, especially in developing markets.
• Regulatory Approvals: Label expansions for indications like pneumocystis pneumonia (PCP) treatment in immunocompromised patients bolster its market presence.

Market Constraints

• Resistance Trends: Growing resistance, notably to TMP/SMX, reduces efficacy in some regions, leading to decreased usage.
• Safety Concerns: Adverse effects like hypersensitivity reactions and hematologic abnormalities limit use in certain populations.
• Emerging Alternatives: Novel antibiotics with broader spectra or fewer side effects threaten SEPTRA's market share.
• Patent Expiry: Original patents have long expired; patent protection is non-existent, leading to price erosion.

Financial Trajectory

• Historical Revenue: Pfizer’s legacy products, including SEPTRA, accounted for roughly $250 million in 2020. The decline aligns with increasing resistance and market share erosion.
• Generic Competition: Since patent expiration (~ late 1990s), generic formulators have dominated sales, with prices dropping by over 50% in the past decade.
• Market Outlook (2023-2028): Modest growth projected at around 2% annually, driven by regional demand in emerging markets and new off-label indications. It is unlikely to see significant revenue growth without formulation or indication expansion.
• Potential Impact of Repositioning: Limited prospects for high-margin repositioning given established generic status and safety profile. However, incremental growth could occur through combination therapies or new formulations targeting resistant strains.

Pricing and Reimbursement Dynamics

• Pricing Trends: Average pharmacy acquisition cost in the U.S. is approximately $0.15 per pill, with retail pricing around $0.25. Price erosion continues as generics flood the market.
• Insurance and Reimbursement: In the U.S., insurance coverage is broad, with most reimbursements covering at least 80% of the drug's cost, supporting steady demand in outpatient settings.
• International Variations: In low-to-middle-income countries, prices are often lower, and reimbursement policies are less structured. Out-of-pocket costs limit access, constraining growth.

Regulatory and Policy Factors

• FDA Approvals: Continued approvals for specific indications such as PCP in immunosuppressed patients.
• Antibiotic Stewardship: Policies emphasizing judicious use may limit prescriptions, impacting sales.
• Innovation & Research: Lack of significant new development reduces the potential for new market entry or expanded indications.

Competitive Landscape

Competitors	Key Features	Market Share (Approximate)	Strengths	Threats
Bactrim (generic)	Cost-effective, established use	70% in the U.S.	Cost favorability	Resistance, safety concerns
Daptomycin, Linezolid	Broader spectrum for resistant strains	10%	Potent against resistant bacteria	Cost, side effect profile
Emerging vaccines	Prevention of bacterial infections	5%	Reduces need for antibiotics	Limited to specific indications

Future Outlook

• No significant patent or formulation innovations are underway.
• Growth largely depends on regional adoption and resistance dynamics.
• Potential for slight increase if used in combination with other agents or for emerging resistant infections.

Key Takeaways

• SEPTRA remains a low-cost antibiotic with a stable but declining market share.
• Resistance and safety issues limit expansion.
• Generic competition exerts downward pressure on prices and revenues.
• Future growth prospects are limited absent significant repositioning efforts.
• Regional uptake in emerging markets may offer incremental gains.

FAQs

1. What factors could revive SEPTRA’s market share?
   Development of new formulations, indication expansions, or reversal of resistance trends.

2. How does resistance impact SEPTRA usage?
   Increasing bacterial resistance leads to reduced clinical efficacy and decreased prescriptions.

3. Are there alternative drugs that threaten SEPTRA's position?
   Yes, newer antibiotics with broader spectra or fewer side effects are competitors, especially for resistant infections.

4. How does patent expiration affect SEPTRA's revenue?
   It allows generic manufacturers to produce cheaper versions, decreasing sales revenue for brand-name products.

5. What regulatory policies influence SEPTRA's sales?
   Antibiotic stewardship programs, safety guidelines, and approval for additional indications shape market dynamics.

References

[1] GlobalData, "Antibiotics Market Analysis," 2022.
[2] IQVIA, "Worldwide Prescription Data," 2022.
[3] U.S. Food & Drug Administration, "Drug Approval and Labeling," 2022.
[4] MarketsandMarkets, "Antibiotics Market Forecast," 2023.